MYL News and Headlines - Mylan NV

GuruFocus Articles Total 139
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

This big pharma has received bad and good news in recent months, but the strength of management may matter more

Pharma companies spend billions on research and development, but sometimes their fortunes are beyond their own control. A case in point: Biogen Inc. (BIIB), which has been whipsawed by two recent events.

In June, a federal district court in West Virginia ruled that a key patent protecting Biogen's top-seller, Tecfidera, was invalid. Biogen lost to the generic drug company Mylan NV (MYL), which is likely to roll out a generic multiple sclerosis medication in the near future. While Biogen said it would appeal the verdict, it is a serious threat to a drug that delivers more than $4 billion in

1655 Views    Robert Abbott    2020-09-03 21:49
Approval of Mylan's copycat of blockbuster Tecfidera sends Biogen shares down

Already on the ropes after a recent patent ruling went against it, Biogen Inc. (BIIB) stock could be down for the count if the company's Alzheimer's drug fails to gain approval. Based on what analysts are saying, the odds of that happening appear to be about 50-50.

Shares of the Cambridge, Massachusetts-based biotech traded as high as $295 earlier in the week, but are down about 6% following news that the British generics specialist Mylan (MYL) had received Food and Drug Administration approval to launch its new Multiple Sclerosis drug.

What's problematic for Biogen is that

133 Views    Barry Cohen    2020-08-21 14:28
Europe-focused Guru invests in energy and retail

Cobas Asset Management recently released its portfolio updates for the second quarter of 2020, which ended on July 30.

Under the management of Chairman and Chief Investment Officer Francisco Garcia Parames (Trades, Portfolio), the asset management company seeks to follow Warren Buffett (Trades, Portfolio)’s value investing strategies, focusing on undervalued assets that show high potential for long-term growth. The firm invests mostly in European companies, but it holds some positions in the United States and Asia as well.

Based on its investing criteria, the firm’s top buys for the second quarter were in G-III

750 Views    Margaret Moran    2020-08-04 21:39
While giants like Gilead Sciences and Pfizer are progressing well, many small players have witnessed setbacks in their Covid-19 research

As the world awaits a potential solution to counter the Covid-19 pandemic, a number of pharma and biotech companies have their candidates going through different stages of trials.

The total number of confirmed Covid-19 cases across the globe is nearing the 12 million mark, with over 3 million in the U.S. alone. Governments have thus been putting increasing pressure on scientists and pharmaceutical companies to come up with a drug or a vaccine to handle the situation. The process has been slow, which was expected as a successful treatment has never before been developed for any other type of coronavirus,

245 Views    Ishan Majumdar    2020-07-08 20:50
The drugmaker offers a dividend yield of almost 4.5%

Pfizer Inc (PFE) has joined the list of High-Yield Dividend Screener & High-Dividend Yield Stocks in Guru's Portfolios.

Based on the share price on Monday, June 22, it offers a dividend yield of 4.43%, more than double the average of the S&P 500, while its share price has been going down—and began going down before Covid-19 was a factor :

GuruFocus Pfizer price chart

Specifically, the price took a dive in the first couple of weeks of July 2019, just before patent protection on the fibromyalgia drug Lyrica expired on July 19th and a generic

1203 Views    Robert Abbott    2020-06-23 18:48
Piper analyst considers OK a longshot and another reason not to be bullish on stock

The need for Biogen Inc. (BIIB) to get its Alzheimer’s drug approved became more urgent this week after the company lost a patent dispute over its top-selling medication.

A West Virginia District Court ruled that a key patent covering Biogen's multiple sclerosis medicine Tecfidera is invalid, a win for the generics company Mylan (MYL), which could have a copycat on the market as early as next year, according to an article in BioPharma Dive.

The disappointing news shaved about $25 off Biogen’s share price this week, but the stock did bounce back, gaining more than $10 on Friday to close

288 Views    Barry Cohen    2020-06-19 21:04
Pricing is increasing for makers of copycat medicines

At least one analyst is predicting Covid-19 could be beneficial to generic drug companies as concerns over the supply chain ease, according to an article in FiercePharma. In fact, prices for generic drugs are increasing, meaning the coronavirus pandemic could boost profits for the makers of copycat medicines.

Early concerns that there would be shortages in the worldwide supply have diminished. In a Wednesday note to investors, Bernstein analyst Ronny Gal said the global generic drug supply is likely to come back strong and record solid growth, although “spot shortages” could still occur.

This would be a welcome development

376 Views    Barry Cohen    2020-03-27 21:45
Guru hedges against potential downsides in the US markets, sells Mylan, invests in Alibaba

Steven Romick (Trades, Portfolio) recently released the portfolio update for the FPA Crescent Fund. During the quarter, the fund’s four largest transactions were short sales of U.S. exhange-traded funds, including the iShares Core S&P 500 ETF (IVV). Its only new buy was Alibaba Group Holding (BABA). The fund also sold out of its holding in Mylan NV (MYL).

The Crescent Fund operates under First Pacific Advisors (Trades, Portfolio) and is managed by Romick, Brian A. Selmo and Mark Landecker. The fund’s objective is to seek returns with less risk than the market while avoiding

453 Views    Margaret Moran    2020-02-07 22:30
Guru's largest existing-position sales of the 4th quarter

Steven Romick (Trades, Portfolio) sold shares of the following holdings during the fourth quarter.


The investor sold out of Mylan NV (MYL). The portfolio was impacted by -1.42%.


The generic pharmaceutical manufacturer has a market cap of $11.18 billion and an enterprise value of $23.97 billion.

GuruFocus gives the company a profitability and growth rating of 7 out of 10. The return on equity of 0.4% and return on assets of 0.15% are underperforming 55% of companies in the drug manufacturers industry. Its financial strength is rated 3 out

119 Views    Tiziano Frateschi    2020-01-20 17:50
Anthem tops the list

The Vanguard Health Care Fund (Trades, Portfolio), which invests at least 80% of its assets in stocks of companies principally related to the health care industry, bought shares of the following stocks in both the second and third quarters.

Anthem Inc. (ANTM)

The fund increased its position by 17.36% in the second quarter and then raised it by 4.17% in the third quarter. The stock has a weight of 2.45% in the portfolio.


The American managed-care organization has a market cap of $68.90 billion. Its revenue of $100.17 billion has grown

200 Views    Tiziano Frateschi    2019-11-07 19:30
Guru stock highlight

Mylan (MYL) continues to face multiple headwinds including a challenging regulatory environment, pricing pressure on generic drugs in the U.S., and slower than expected regulatory approval of new products. We used the recent merger announcement between Mylan and the Upjohn division of Pfizer as an opportunity to trim into strength.

From [url=]Steven Romick[/url] ([url=]Trades[/url], [url=]Portfolio[/url])'s FPA Crescent Fund 3rd-quarter 2019 commentary.

59 Views    Sydnee Gatewood    2019-10-28 21:51
Company's recent moves will enable it to concentrate on building core business

If it’s true that busy hands are happy hands, then the management team at Pfizer Inc. (PFE) must be ecstatic.

In just the past few months, the company has:

  • Agreed to spin off Upjohn, the manufacturer of Pfizer’s drugs that no longer enjoy patent protection, and combine the unit with Mylan (MYL), a U.K-based generic company.
  • Acquired Array to boost its biotech pipeline in a deal valued at about $11.4 billion.
  • Announced it is investing $500 million in a gene therapy manufacturing plant in North Carolina to complement money it has already socked into other facilities aimed at producing
245 Views    Barry Cohen    2019-09-11 18:50
Fund's largest buys of the 2nd quarter

The Vanguard Health Care Fund (Trades, Portfolio) bought shares of the following stocks during the second quarter.

The fund established a new position in Pfizer Inc. (PFE), buying 22.29 million shares. The trade had an impact of 2.22% on the portfolio.


The pharmaceutical company has a market cap of $212.67 billion and an enterprise value of $246.56 billion.

GuruFocus gives the company a profitability and growth rating of 7 out of 10. The return on equity of 18.97% and return on assets of 7.79% are outperforming 51% of

190 Views    Tiziano Frateschi    2019-08-05 18:26
Buying Teva on the assumption that it is now a takeover target is risky. Here's why

Now that Pfizer (PFE)'s Upjohn and Mylan (MYL) are combining in a new spinoff, it looks like Teva (TEVA) could be next. Judging by price movements in Teva since Pfizer made its move, some traders may be anticipating this. The stock is up nearly 7% since the deal was announced.

But buying Teva on the assumption of it being acquired is more risky than it looks, even at these levels. Here’s why.

First, it can hardly be said that Pfizer and Mylan joining forces is good for Teva in any fundamental sense. The new company will have a healthier balance

350 Views    Matt Winkler    2019-08-02 16:09
Anadarko Petroleum reports better-than-expected results

Dow stocks was higher on Monday, with 3M Co. (MMM) and Johnson & Johnson (JNJ) pulling the index up. The Dow Jones Industrial Average gained 0.15% to 27,234, the S&P 500 index fell 0.16% to 3,020 and the NasdaqComposite Index dipped 0.51% to 8,288.

Shares of Anadarko Petroleum Corp. (APC) slid more than 0.5% after the company announced second-quarter results. It posted earnings of 51 cents per share on $3.44 billion in revenue, reflecting 4.6% growth

23 Views    Omar Venerio    2019-07-29 19:45
The all-stock deal will create new pharmaceutical company

Drugmaker Pfizer Inc. (PFE) announced on Monday it is combining its off-patent drug business, which is called Upjohn, with Pittsburgh-based generic pharmaceutical giant Mylan NV (MYL) in an all-stock deal, creating a new company.

According to the terms of the agreement, each share of Mylan will be converted into one share of the new company, which will be domiciled in the U.S. and renamed and rebranded upon closing. The deal will be structured as a reverse Morris trust, in which Upjohn will be divested from the New York-based company and then combined with Mylan.

Once the deal closes, Pfizer

111 Views    Sydnee Gatewood    2019-07-29 18:05
Company is being pummeled by lawsuits, disappointing results and pricing pressures in generic market

Mylan NV (MYL) might be a good case study for MBA candidates on how not to run a company.

Students would probably find many of the company’s moves comical, but investors aren't laughing. Mylan is one of the worst-performing Dow stocks this year. And since April 2015, shares of the Pittsburgh-based generic pharmaceutical giant have lost 75% of their value. That was about the time Mylan rejected Teva Pharmaceutical’s (TEVA) offer to buy the company for $82 a share.

Wouldn’t Mylan love to have a do-over? At the time, Executive Chairman Robert Coury summarily dismissed the Teva offer because he

978 Views    Barry Cohen    2019-06-11 21:12
Pharmaceutical company posts 1st-quarter earnings

Drugmaker Mylan NV (MYL) reported disheartening first-quarter results before the opening bell on Tuesday, sending shares lower in premarket trading.

The British pharmaceutical company, which also has offices in Pennsylvania, posted a $25 million net loss, or 5 cents per share, for the quarter. Adjusted earnings of 82 cents per share beat Refinitiv’s estimates of 79 cents, but were down 15% from a year ago.

Total revenue declined 7% from the prior-year quarter to $2.5 billion, missing expectations of $2.69 billion. The company attributed the mediocre performance to manufacturing problems and restructuring efforts at its Morgantown plant in West

225 Views    Sydnee Gatewood    2019-05-07 16:04
Bristol-Myers Squibb Co., Annaly Capital Management Inc., Newell Brands Inc. and Mylan NV have declined to their respective three-year lows

Bristol-Myers Squibb Company (BMY), Annaly Capital Management Inc. (NLY), Newell Brands Inc. (NWL) and Mylan NV (MYL) have declined to their three-year lows.

Bristol-Myers Squibb Company (BMY) declined to $45.57

The prices of CVS Health Corp (CVS) shares have declined to $52.81, which is only 2.0% above the 3-year low of $51.77.

Bristol-Myers Squibb Company is an American international pharmaceutical company that manufactures prescription pharmaceuticals in various therapeutic areas including cancer, cardiovascular diseases, diabetes, hepatitis, and HIV.

Bristol-Myers Squibb Company has a market cap of $74.4 billion; its shares were traded around $45.57 with a P/E ratio of 15.02 and

77 Views    Shuda Xia    2019-04-14 15:15
MongoDB advances on earnings beat

U.S. stocks were mostly lower Thursday on concerns regarding the U.S.-China trade deal, with a meeting between President Donald Trump and Chinese President Xi Jinping pushed back to April. The Dow Jones Industrial Average advanced 0.03% to 25,710, the S&P 500 Index fell 0.06% to 2,809 and the Nasdaq Composite Index slid 0.08% to 7,637.

Shares of MongoDB Inc. (MDB) jumped almost 27% after the company announced fourth-quarter results Thursday evening. Revenue grew 70.8% from the prior-year quarter to $85.5 million, beating expectations by $11.48 million. The company reported a loss of 17 cents per share, topping estimates by 21

6 Views    Omar Venerio    2019-03-14 20:45

Headlines Total 107
  • 1
  • 2

2020-10-07 $ 14.91 (0.27%)
2020-09-22 $ 14.82 (0.27%)
2020-09-17 $ 16.16 (1%)
2020-09-09 $ 15.25 (-2.49%)
2020-08-14 $ 16.19 (0.31%)
2020-08-07 $ 16.36 (-0.37%)
2020-08-06 $ 16.42 (-2.84%)
2020-07-30 $ 16.33 (-3.94%)
2020-07-29 $ 17 (5.2%)
2020-07-28 $ 16.16 (-0.37%)
2020-07-10 $ 16.1 (1.39%)
2020-07-07 $ 16.11 (-2.6%)
2020-07-01 $ 15.76 (-1.99%)
2020-06-30 $ 16.08 (0.56%)
2020-06-22 $ 16.46 (1.86%)
2020-06-19 $ 16.16 (-1.04%)
2020-06-17 $ 15.97 (-0.99%)
2020-06-16 $ 16.13 (1.45%)
2020-06-15 $ 15.9 (-0.25%)
2020-06-12 $ 15.94 (-2.21%)
2020-06-10 $ 17.32 (-6.12%)
2020-06-03 $ 17.54 (0.34%)
2020-05-22 $ 15.64 (-2.25%)
2020-05-14 $ 15.22 (-2.06%)
2020-05-12 $ 16.23 (-4.25%)
2020-05-11 $ 16.95 (-3.53%)
2020-05-08 $ 17.57 (1.44%)
2020-05-07 $ 17.32 (2.67%)
2020-05-06 $ 16.87 (1.81%)
2020-05-04 $ 16.52 (2.42%)
2020-04-30 $ 16.77 (-3.18%)
2020-04-28 $ 16.44 (1.86%)
2020-04-27 $ 16.14 (2.41%)
2020-04-24 $ 15.76 (3.01%)
2020-04-23 $ 15.3 (2.62%)
2020-04-17 $ 16.11 (3.94%)
2020-04-02 $ 13.92 (-2.38%)
2020-03-30 $ 15.07 (1.28%)
2020-03-27 $ 14.88 (-4.25%)
2020-03-26 $ 15.54 (4.09%)
2020-02-17 $ 21.9 (%)
2020-02-01 $ 21.42 (-2.28%)
2020-01-28 $ 21.16 (-3.16%)
2020-01-23 $ 21.79 (0.65%)
2020-01-20 $ 21.66 (%)
2020-01-18 $ 21.66 (-1.41%)
2020-01-14 $ 20.78 (-0.34%)
2019-12-20 $ 19.79 (2.12%)
2019-11-07 $ 17.01 (-0.93%)
2019-10-28 $ 18.97 (1.44%)
2019-09-04 $ 19.74 (2.44%)
2019-07-15 $ 18.97 (-1.3%)
2019-06-11 $ 17.51 (-0.34%)
2019-05-07 $ 21.53 (-23.81%)
2019-03-18 $ 28.18 (0.32%)
2019-02-27 $ 26.01 (-15.06%)
2019-02-21 $ 31.06 (-1.77%)
2018-10-09 $ 34.61 (-1.98%)
2018-02-09 $ 39.28 (0.08%)
2017-12-05 $ 37.41 (-0.08%)
2017-10-11 $ 38.29 (-0.42%)
2017-09-26 $ 31.13 (-1.11%)
2017-07-10 $ 37.72 (0.29%)
2017-06-01 $ 39.56 (1.49%)
2017-05-09 $ 38.01 (1.69%)
2017-03-24 $ 40.96 (-1.56%)
2016-11-18 $ 36.47 (-2.9%)
Weak Outlook on Mylan -
2016-11-10 $ 38.28 (-1.64%)
2016-10-20 $ 37.61 (1.1%)
2016-04-26 $ 44.99 (-0.07%)
2016-02-03 $ 52.26 (2.83%)
2016-01-19 $ 50.22 (1.03%)
2015-11-03 $ 46.57 (1.66%)
2015-03-27 $ 61.63 (-0.4%)
Total 107
  • 1
  • 2